Abstract
The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Apoptosis / drug effects
-
Apoptosis / genetics*
-
Cladribine / administration & dosage*
-
Cladribine / adverse effects
-
Cluster Analysis
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / adverse effects
-
DNA Mutational Analysis
-
Female
-
Gene Expression Profiling
-
Gene Expression Regulation, Leukemic / drug effects
-
Genes, Immunoglobulin Heavy Chain / genetics
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Male
-
Middle Aged
-
Pilot Projects
-
Rituximab
-
V(D)J Recombination / drug effects
-
V(D)J Recombination / genetics
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Cladribine
-
Rituximab
-
Cyclophosphamide